Method of Enhancing Opsonophagocytosis


This invention aims to bolster the human body's own mechanisms to fight infection by enhancing an innate immune response, opsonophagocytosis. The specific 24 amino acid sequence (P4) acts as a polymorphonuclear cell activator. P4 can be administered in vivo along with a disease's specific antibody to enhance systemic bacterial clearance, thus leading to prolonged survival. This technology enhances the body's response to infections such as S. pneumoniae and S. aureus.

Potential Commercial Applications: Competitive Advantages:
  • Opsonic therapy
  • Passive immunization
  • Enhancement of pathogen clearing
  • Synergistic use with other therapies
 
  • Multiple in vivo studies indicate significant improvements in recipient outcomes
  • Highly adaptable and can be combined with a number of alternate therapies
  • Enhances opsonophagoctyosis to achieve therapeutically effective results


Development Stage:
  • Pre-clinical
  • In vitro data available
  • In vivo data available (animal)


Inventors:

Edwin Ades (CDC)  ➽ more inventions...

GowriSankar Rajam (CDC)  ➽ more inventions...

Sandra Steiner (CDC)  ➽ more inventions...

George Carlone (CDC)  ➽ more inventions...

Nikkol Atwell-Melnick Melnick (CDC)  ➽ more inventions...

Jacquelyn Sampson (CDC)  ➽ more inventions...

Joseph Martinez (CDC)  ➽ more inventions...

Julile Skinnner (CDC)  ➽ more inventions...

Joseph Caba (CDC)  ➽ more inventions...


Intellectual Property:
U.S. Pat: 8,431,134 issued 2013-04-30
U.S. Pat: 9,101,582 issued 2015-08-11
U.S. Pat: 7,919,104 issued 2011-04-05
US Application No. 13/056,522
US Application No. 13/851,508
PCT Application No. PCT/US2005/027290
US Application No. 11/992,719
Various foreign counterparts such as in Australia, Europe, Hong Kong, and Canada.

Publications:
Melnick N, et al. PMID 19386795
Weeks JN, et al. PMID 21383090
Bangert M, et al. PMID 22457294

Collaboration Opportunity:

The Centers for Disease Control and Prevention (CDC) is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate or commercialize Methods and Tools for Enhancing Opsonophagocytosis in Response to a Pathogen. For collaboration opportunities, please contact Suzanne Shope at sshope@cdc.gov or 770-488-8613.


Licensing Contact:
Karen Surabian, J.D., M.B.A.
Email: karen.surabian@nih.gov
Phone: 301-594-9719

OTT Reference No: E-329-2013-0
Updated: May 7, 2018